MC3 Recorded Education Series: PREP Module: Screening for Early Psychosis in Primary Care Settings
To begin this activity, click Enroll. Once logged in, learners can access educational content, assessments, and evaluations. Learners who successfully complete the activity will be able to print a certificate.
Release Date:
Wed, 1/1/20
Termination Date:
Thu, 12/31/20
Credits:
0.5
Description:
This presentation will teach clinicians to identify the diagnostic criteria for clinical high-risk psychosis (attenuated psychosis syndrome), have an approach to the evaluation of young adults with suspected emerging psychotic disorders, understand the non-pharmacologic and pharmacologic approaches for the treatment of attenuated psychosis syndrome, and referral resources for further evaluation.
Educational Objectives:
At the end of this activity, participant should be able to:
- Define the difference between psychosis and schizophrenia
- Understand the 3 phases of schizophrenia
- Understand the importance of early identification and intervention of psychosis
- Understand the definition of attenuated psychosis syndrome
- Understand the evidence based non-pharmacological and pharmacological treatment for early psychosis
- Identify referral sources for evaluation and treatment of early psychotic disorders in youth
Target Audience:
This activity is appropriate for House Officers, Medical Students, Nurse Practitioners, Nurses, Other Healthcare Professionals, Physician Assistants, Physicians, Social Workers in the fields of Adolescent Medicine, Family Medicine, Pediatrics, Primary Care, Psychiatry, Psychology, Social Work.
Accreditation and Credit Designation:
Termination Date: April 2022
The University of Michigan Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Michigan Medical School designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Release Date: May 2019Termination Date: April 2022
Additional Info:
Presenters:
Alyssa Smith, LLP
Stephan Taylor, MD
Educational Planner
Stephan Taylor, MD
Educational Co-Planner
Anne Kramer, MSW
Erin Hughes-Krieger, MSW
Ivy F Tso, PH.D.
Financial Disclosures:
There are no relevant financial relationships with ACCME-defined commercial interests to disclose for this activity.
References:
Addington, J., et al. 2010. A randomized controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophrenia Research, 125: 54-64.
Addington, J., et al. 2015. Duration of untreated psychosis in community treatment settings in the United States. Psychiatric Services, 66: 753-756.
Addington, J., et al. 2015. North American prodrome longitudinal study (NAPLS 2): The prodromal symptoms. Journal of Nervous & Mental Disease, 203(5): 328-335.
Cannon TD, et al. 2016. An Individualized Risk Calculator for Research in Prodromal Psychosis. Am J Psychiatry, 173:980-988
Cloutier, M., et al. 2016. The economic burden of schizophrenia in the United States in 2013. Journal of Clinical Psychiatry, 77(6): 764-771.
Fusar-Poli, P., et al. 2012. Predicting psychosis: Meta-analysis of transition outcomes in individuals at clinical high risk. Journal of American Medical Association, 69(3): 220-229.
Loewy, R.L., et al. 2011. Psychosis risk screening with the prodromal questionnaire – brief Version (PQ-B). Schizophrenia Research, 129: 42-46.
Register-Brown K, Hong LE, 2014. Reliability and validity of methods for measuring the duration of untreated psychosis: a quantitative review and meta-analysis. Schizophrenia Research, 160:20-26
Seidman, L., et al. 2010. Neuropsychology of the prodrome to psychosis in the NAPLS consortium: Relationship to family history and conversion to psychosis. Journal of American Medical Association.67(6): 578-588. Sommer, I., et al. 2012. The treatment of hallucinations in schizophrenia spectrum disorders. Schizophrenia Bulletin, 38(4): 704-714.
Tarrier, N. 2005. Cognitive behaviour therapy for schizophrenia: A review of development, evidence and implementation. Psychotherapy and Psychosomatics, 74:136-144.
Trotman, H., et al. 2013. The development of psychotic disorders in adolescence: A potential role for hormones. Hormones & Behavior, 64(2): 411-419.
Van der Gaag, M., Van den Berg, D., Ising, H. 2019. CBT in the prevention of psychosis and other severe mental disorders in patients with an at risk mental state: A review and proposed next steps. Schizophrenia Research, 203: 88-93.
Woods, S., et al. 2009. Validity of the prodromal risk syndrome for first episode psychosis: Findings from the North American prodrome longitudinal study. Schizophrenia Bulletin (35)4: 894-908.
Yung, A. R., McGorry, P. D. 1996. The prodromal phase of first-episode psychosis: Past and current conceptualizations. Schizophrenia Bulletin, 22(2): 353-370.
Alyssa Smith, LLP
Stephan Taylor, MD
Educational Planner
Stephan Taylor, MD
Educational Co-Planner
Anne Kramer, MSW
Erin Hughes-Krieger, MSW
Ivy F Tso, PH.D.
Financial Disclosures:
There are no relevant financial relationships with ACCME-defined commercial interests to disclose for this activity.
References:
Addington, J., et al. 2010. A randomized controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophrenia Research, 125: 54-64.
Addington, J., et al. 2015. Duration of untreated psychosis in community treatment settings in the United States. Psychiatric Services, 66: 753-756.
Addington, J., et al. 2015. North American prodrome longitudinal study (NAPLS 2): The prodromal symptoms. Journal of Nervous & Mental Disease, 203(5): 328-335.
Cannon TD, et al. 2016. An Individualized Risk Calculator for Research in Prodromal Psychosis. Am J Psychiatry, 173:980-988
Cloutier, M., et al. 2016. The economic burden of schizophrenia in the United States in 2013. Journal of Clinical Psychiatry, 77(6): 764-771.
Fusar-Poli, P., et al. 2012. Predicting psychosis: Meta-analysis of transition outcomes in individuals at clinical high risk. Journal of American Medical Association, 69(3): 220-229.
Loewy, R.L., et al. 2011. Psychosis risk screening with the prodromal questionnaire – brief Version (PQ-B). Schizophrenia Research, 129: 42-46.
Register-Brown K, Hong LE, 2014. Reliability and validity of methods for measuring the duration of untreated psychosis: a quantitative review and meta-analysis. Schizophrenia Research, 160:20-26
Seidman, L., et al. 2010. Neuropsychology of the prodrome to psychosis in the NAPLS consortium: Relationship to family history and conversion to psychosis. Journal of American Medical Association.67(6): 578-588. Sommer, I., et al. 2012. The treatment of hallucinations in schizophrenia spectrum disorders. Schizophrenia Bulletin, 38(4): 704-714.
Tarrier, N. 2005. Cognitive behaviour therapy for schizophrenia: A review of development, evidence and implementation. Psychotherapy and Psychosomatics, 74:136-144.
Trotman, H., et al. 2013. The development of psychotic disorders in adolescence: A potential role for hormones. Hormones & Behavior, 64(2): 411-419.
Van der Gaag, M., Van den Berg, D., Ising, H. 2019. CBT in the prevention of psychosis and other severe mental disorders in patients with an at risk mental state: A review and proposed next steps. Schizophrenia Research, 203: 88-93.
Woods, S., et al. 2009. Validity of the prodromal risk syndrome for first episode psychosis: Findings from the North American prodrome longitudinal study. Schizophrenia Bulletin (35)4: 894-908.
Yung, A. R., McGorry, P. D. 1996. The prodromal phase of first-episode psychosis: Past and current conceptualizations. Schizophrenia Bulletin, 22(2): 353-370.
Credits available:
AMA PRA Category 1: 0.50
Participation: 0.50
